Mount Sinai Innovation Partners

Mount Sinai Innovation Partners

Mount Sinai Innovation Partners (MSIP) launched in 2014 as the formal technology transfer and venture office for the Mount Sinai Health System, the largest academic medical center in New York City. President Erik Lium, who previously built the commercialization function at UCSF, was recruited to professionalize what had been a traditional tech-transfer office into an institution that both licenses intellectual property and spins out venture-funded companies built on faculty research. The unit sits atop a health system that employs over 3,000 faculty, operates eight hospital campuses, and awards more than $500 million annually in NIH and industry-sponsored research — a volume that places Mount Sinai consistently in the top 20 U.S. medical schools for research awards. MSIP occupies a hybrid mandate unusual among academic venture arms: it makes direct seed- and early-stage equity investments through Mount Sinai's own balance-sheet vehicle, the i3 Asset Accelerator, while also syndicating spinout rounds to external venture firms. Therapeutic areas track Mount Sinai's departmental strengths, with confirmed activity in oncology, immunology, neuroscience, digital health, and artificial intelligence applied to clinical workflows. Portfolio companies have included RenalytixAI, a kidney-disease diagnostics platform that went public on Nasdaq, and OOVA, a fertility-tracking digital health company. The office discloses that Mount Sinai participates in such spinouts by contributing intellectual property, providing clinical validation through its hospital network, and retaining equity stakes that align the system's financial interests with each company's long-term outcomes. Geographic focus centers on New York but extends to co-investments with Boston- and San Francisco-based life-science funds. The unit discloses it has negotiated more than 2,000 license agreements and launched over 50 startups since inception, though total fund size and committed capital are not public. MSIP maintains its headquarters on the Icahn School of Medicine campus in Manhattan and draws its pipeline directly from faculty disclosures, which the institution manages through a dedicated invention-evaluation process. In addition to the venture portfolio, the office houses Mount Sinai's corporate partnering group, which structures research collaborations and license deals with pharmaceutical and med-tech companies, providing a parallel commercialization track for assets that are not spun into standalone companies. The institution has not publicly disclosed a separate fund close in recent years; its investment capacity appears tied to health-system reserves rather than external limited partners. No other academic medical center in the United States combines a proprietary clinical-trial infrastructure for its own spinouts with a dedicated in-house venture investment vehicle at quite this scale — a structural advantage that effectively makes Mount Sinai the first patient-adoption site for every digital tool and therapeutic it incubates. MSIP is not structured as a limited partnership and does not report to external investors, which shields it from conventional fund-timing pressure and allows the office to hold positions through regulatory cycles that would exhaust standard venture-fund lifespans. That architecture, and its deep tether to a single academic health system, distinguishes it from both independent health-tech venture firms and university pure-play tech-transfer offices.